Fiore Rx Antifungal Nail Lacquer Claims Clipped At NAD After Avoiding FTC

NAD welcomes Fiore RX back to the self-regulatory process one year after referring its Fiore Rx Antifungal Nail Lacquer claims to FTC due to the company’s unresponsiveness. The review does not go favorably for the firm, which must discontinue or modify all 22 claims targeted by NAD in its inquiry for lack of substantiating evidence.